SeaStar Medical Holding Corp (ICU): Nasdaq/NYSE listing notice — SeaStar Medical receives Nasdaq delisting notice for failing minimum market value rule

SeaStar Medical Holding Corp

Nasdaq notified SeaStar on Dec 24, 2024 that it failed to regain compliance with $35M minimum market value of listed securities.
Securities (ICU, ICUCW) are subject to delisting from Nasdaq on Jan 3, 2025 unless Company appeals by Dec 31, 2024.
Company intends to appeal delisting determination before Nasdaq Hearings Panel; appeal stays delisting pending outcome.
SeaStar was previously notified of non-compliance on June 24, 2024 and has not regained compliance since.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

SeaStar Medical Holding Corp received a nasdaq delisting notice notice regarding market value (rules 5550(b)(2)).

Exchange: nasdaq
Notice: delisting notice
Deficiency: market value
Rules: 5550(b)(2)

Exact text from the filing

December 24, 2024, the Company received written notification (the “Notification”) from Nasdaq stating that the Company had not regained compliance with the Rule. Pursuant to the Notification, the Securities are subject to delisting from Nasdaq on January 3, 2025, unless the Company requests a hearing before the Nasdaq Hearings Panel (the “Panel”) by December 31, 2024. The Company intends to appeal the delisting determination before the Panel and regain compliance with the Rule. Under Nasdaq rules, the delisting of the Securities will be stayed during the pendency of the appeal and during such

View on SEC.gov

Browse all listing & compliance notices →

SeaStar Medical Holding Corp filing history →

Source: SEC EDGAR

accession 0001213900-24-112673

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.